The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Official Title: Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer
Study ID: NCT04137822
Brief Summary: An Expanded Access Program for IMM-101 for patients with advanced pancreatic cancer.
Detailed Description: IMM-101 is a suspension of heat-killed whole cell Mycobacterium obuense. Since it is a heat-killed preparation, treatment is not associated with the potential side-effects of delivering live or attenuated organisms. Five studies with IMM-101 have been completed including a 110-patient randomised Phase II study in pancreatic cancer and exploratory studies in other solid tumours (melanoma, colorectal cancer and advanced melanoma).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
France, Paris, , France
UK, London, , United Kingdom